Mobocertinib (TAK-788, Exkivity®) (Figure 26) is the latest third-generation EGFR inhibitor approved for the treatment of locally advanced or metastatic NSCLC with exon 20 insertion, following an accelerated approval by the FDA in 2021 [192,193,194,195]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.